Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Alimera Sciences To Present At UBS Global Healthcare Conference

ALIM

ATLANTA, May 11, 2015 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its management will present at the UBS Global Healthcare Conference in New York.

Dan Myers, President and Chief Executive Officer, is scheduled to present on Monday, May 18, 2015 at 1:30 p.m. ET. The presentation will be webcast live and will be available for access on the Investor Relations section of the corporate website at www.alimerasciences.com. For those who are not available to listen to the live broadcast, the webcast will be archived for 90 days.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., headquartered in Alpharetta, Georgia, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera's European operations are conducted from London by its subsidiary, Alimera Sciences Limited, which has offices in Aldershot, U.K., Berlin, Germany and Lisbon, Portugal.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/alimera-sciences-to-present-at-ubs-global-healthcare-conference-300080511.html

SOURCE Alimera Sciences, Inc.